Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes

An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes

This is a multi-center, open-label, parallel-group, randomized controlled study in subjects with type 2 diabetes using multiple daily injection (MDI) insulin therapy. Subjects will be randomized to either receive the DC App and BD Nano 2nd Gen pen needles (intervention) or continue their standard of care using their current pen needle and diabetes management (control). The study will consist of four visits and two scheduled phone calls across a total of 10 weeks.

Study Overview

• Status: Terminated
• Conditions: Diabetes Mellitus, Type 2
• Intervention / Treatment: Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle

Detailed Description

At Visit 1 (Day -14) site staff will screen and enroll qualified subjects, provide a BGM (Accu-Chek Guide) and attach a blinded flash glucose sensor (Libre Freestyle) to the back of the arm. Subjects will complete any applicable baseline Patient Reported Outcomes (PRO) questionnaires and be sent home with no changes to their current therapy. While at home Subjects will be asked to test blood glucoses using the provided BGM and continue their usual insulin dosing before returning to clinic for Visit 2. Visit 2 will consist of randomization (Interventional Group or Control Group). The control group will be continued on their current pen needle and receive standard visit education as needed. The intervention group will be trained on the use of the DC App and be switched to BD Nano 2nd Gen pen needle. During weeks 3 through 8, subjects in both groups will continue their usual insulin routine, with the control group adhering to their usual practice of managing their diabetes and the intervention group utilizing the DC app for relevant educational content and tips plus using the BD Nano 2nd Gen for all insulin injections. During Visit 3 subjects will get a 2nd fGM sensor placed and be instructed to continue their insulin routine for the final 2 weeks. Visit 4 is the last visit where subjects will have their fGM removed, return the BGM, complete applicable PRO surveys, an injection technique questionnaire and be discharged.

• Study Type: Interventional
• Enrollment (Actual): 58
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • San Mateo, California, United States, 94401
      • Mills Pennisula Medical Center-Diabetes Research Institute
  • Florida
    • West Palm Beach, Florida, United States, 33401
      • Metabolic Research Institute
  • Hawaii
    • Honolulu, Hawaii, United States, 96814
      • East West Medical Research Institute
  • Texas
    • Austin, Texas, United States, 78749
      • Texas Diabetes and Endocrinology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 22 years of age minimum
2. Adult subjects with type 2 diabetes mellitus on Multiple daily injections (MDI) and giving themselves at least 2 injections of insulin / day using a pen injector. This may include at minimum i. giving 1 basal injection and at least 1 meal time injection or ii. giving at least 2 daily injections of mixed insulins or iii. giving 2 meal time injections iv. two injections of basal insulin per day will not be considered MDI for this study v. additional OAD/non-insulin injectable therapy is acceptable
3. Must currently be on MDI insulin therapy for at least 6 months prior to enrollment and, in the opinion of the investigator, would benefit from dose optimization.
4. Willing to use the BD provided BGM for the study duration.
5. Hemoglobin A1C of 8.0 - 11% at screening (tested at enrollment unless Subject has a documented HbA1c value on file at the site that was drawn within 3 months of enrollment date).
6. In stable health status with no acute or significant illness, based on the opinion of the investigator.
7. Able to read, write and follow instructions in English (translations will not be provided).
8. Currently using a smartphone and able to understand the use of mobile apps.
9. Able and willing to provide informed consent.
10. Able and willing to follow study procedures.

Exclusion Criteria:

• Subjects with any one of the following characteristics will be excluded from participation:

  1. Pregnant or breast feeding- self reported.
  2. Subject on basal-only
  3. Uncontrolled comorbidities or acute illness
  4. Currently using Nano 2nd Gen pen needles
  5. Use of a smartphone with iOS 10.0 or lower or with Android OS 5.0 "Lollipop" or lower

  6. Use of CGM or fGM less than 6 months and not proficient in its use, however this may be left up to the investigators discretion.

     i. Subjects may continue to wear their own CGM/fGM during their participation in this study if they adhere to the testing of blood glucose using the site provided BGM.

  7. Subjects not on stable doses of concomitant non-insulin diabetes medications. Stable is defined as not requiring new non-insulin diabetes medications or any changes in dosing of current non-insulin diabetes medication during study participation (10 weeks) unless warranted by investigator for the safety of the subject.
  8. Actively using one of the following diabetes management apps deemed similar and not willing to stop using it during participation on the study (exclusionary apps; Onedrop, Welldoc (Bluestar), Dario, Sugar Sense Glucose, Buddy, mySugr, Omada, Livongo, Accu-Check Connect, SugarIQ).
  9. Known sensitivity to adhesives.
  10. Currently using the DC app.
  11. Employed by, or currently serving as a contractor or consultant to BD or study site
  12. Any other condition the investigator deems to pose a risk to the Subject in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: SUPPORTIVE_CARE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: App plus Nano; Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin	Device: BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle; Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
NO_INTERVENTION: Standard Care; Standard of Care/Subject is to continue on their current diabetes management regime

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES) From Baseline to End of Study	A standardized questionnaire including 8 questions with response categories of 'strongly disagree', 'somewhat disagree', 'neutral', 'somewhat agree', and 'strongly agree'. An overall score for the DES is calculated by summing all of the item scores and dividing by 8 for a possible score range of 1-5 where a higher score indicates a higher level of empowerment.	Baseline (Day -14) and Study End (Day 56)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in 24 Hour Average Blood Glucose From Baseline to End of Study	Freestyle Libre Pro blinded flash glucose monitoring will be used to assess change in average 24 hour blood glucose between groups Subjects will wear Libre sensors on the backs of their arm for the 2 weeks at the beginning of the study and 2 weeks at the end of the study.	Baseline (Day -14 through Day -1) and Study End (Day 42 through Day 56)
Blood Glucose Values in Range of <54 mg/dL at Baseline Compared to End of Study	Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end. For example, Time below 54 mg/dl is calculated in the following manner: Number of all glucose data points below 54 mg/dl / total number of glucose data points X 100. Since data points are all 5 minutes apart, this calculation provides the percentage of time in that range.	Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Blood Glucose Values in Range of <70 mg/dL at Baseline Compared to End of Study	Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end.	Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Blood Glucose Values Between 70 mg/dL and 180 mg/dL at Baseline Compared to End of Study	Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end.	Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Blood Glucose Values in Range of >180mg/dL at Baseline Compared to End of Study	Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end.	Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Blood Glucose Values in Range of >250 mg/dL at Baseline Compared to End of Study	Data collected by the flash glucose monitor were used to calculate percent of time in range to compare differences between groups at baseline and study end.	Baseline (Day -14 through Day -1) and Study End (Day 42-through Day 56)
Change in Mean Amplitude of Glycemic Excursion (MAGE) Between Baseline and End of Study	Flash glucose monitoring data were used to measure glycemic variability changes at baseline and study end between groups. Measuring glycemic variability helps determine how much glucose levels change over the course of a day or between days.	Baseline (Day -14 through Day -1) and Study End (Day 42 through Day 56)
Change in Diabetes Distress Screening Scale - 17 (DDS17) Scores From Baseline to End of Study	A standardized questionnaire including 17, 6-point Likert Scale questions where 1 indicates "Not a problem", 2 indicates "A slight problem", 3 means "A moderate problem", 4 indicates a "Somewhat serious problem", 5 indicates "A serious problem", and 6 means "A very serious problem". Using this scale, a Total Score, Emotional Burden Score, Physician Score, Regimen Distress Score, and Interpersonal Score were calculated.	Baseline (Day -14) to Study End (Day 56)
Insulin Delivery System Rating Questionnaire (IDSRQ) Scores at Baseline and End of Study	A standardized questionnaire including several questions with ordinal response scales from 1 to 4 and 1 to 5. The IDSRQ has seven sub-scales (satisfaction, interference of treatment with daily activities, diabetes-related worries, clinical efficacy, psychological well-being, social burden, and treatment preference). Each sub-scale is calculated as a mean of their corresponding items with scores ranging from 0-100. Higher scores represent higher levels of satisfaction, perceived clinical efficacy, and psychological well-being, interference with daily activities, diabetes-related worries, and social burden.	Baseline (Day -14) and Study End (Day 56)
Adherence to Refills and Medications Scale for Diabetes (ARMS-D) Questionnaire Scores at Baseline and Study End	A standardized questionnaire including 11 multiple choice questions. The ARMS-D yields a total score plus two sub-scale scores (refill sub-scale and medication taking sub-scale. Items 1-10 are scored as follows: 1= none of the time, 2 = some of the time, 3 = most of the time, and 4 = all of the time. Item 11 is reversed scored. The ARMS-D total is a sum of all items for a possible score ranging from 11-44. The ARMS-D refill sub-scale is a sum of 4 items for a possible score ranging from 4-16. The ARMS-D medication taking sub-scale is a sum of 7 items for a possible score ranging from 7-28. Lower scores indicate better adherence.	Baseline (Day -14) to Study End (Day 56)
Patient Satisfaction at Study End	A questionnaire including 16, 5-point Likert Scale questions where 1 indicates strongly disagree and 5 indicates strongly agree. This questionnaire yields a total satisfaction score plus three sub-scale scores (mobile app satisfaction, pen needle satisfaction, and injection management system satisfaction). The total score ranges from 16-80. The mobile app and pen needle satisfaction sub-scale score range from 6-30 and is a sum of all items in the associated sub-scale. The management system sub-scale score ranges from 4-20 and is a sum of all items in the sub-scale. Higher scores indicate higher satisfaction.	Administered to participants in the Intervention group only at end of study (Day 56)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Hypoglycemic Events (<70mg/dL and <54mg/dL) at Baseline and Study End	Frequency of hypoglycemia: The number of hypoglycemic events (<70mg/dL and <54mg/dL) as measured by blood glucose monitor (BGM) will be collected to determine frequency of hypoglycemia in each group.	Baseline (Day -14) to Study End (Day 56)
Number of Hours of Patient Engagement With App	Patient Engagement: Engagement with The DC App will be measured by app collected usage analytics and main assessment was time spent within app.	Baseline (Day 1) to Study End (Day 56)

Collaborators and Investigators

• Sponsor: Becton, Dickinson and Company
• Investigators: Study Director: Edward Mahoney, PhD, Becton Dickinson; Principal Investigator: David Klonoff, M.D, FACP, Diabetes Research Institute, Mills-Peninsula Medical Center, California

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 6, 2019
• Primary Completion (ACTUAL): June 12, 2020
• Study Completion (ACTUAL): June 12, 2020

Study Registration Dates

• First Submitted: August 28, 2019
• First Submitted That Met QC Criteria: September 12, 2019
• First Posted (ACTUAL): September 16, 2019

Study Record Updates

• Last Update Posted (ACTUAL): July 8, 2021
• Last Update Submitted That Met QC Criteria: June 16, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2
• Other Study ID Numbers: DBC-19BRGHT02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No